Novocure<br><span>at SNO</span>

at SNO

Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.

Learn more
a strategic<br><span>alliance</span>

a strategic

Novocure and the NYU Grossman School of Medicine’s Department of Radiation Oncology entered into a strategic alliance that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields.

Learn more
investing in <br><span>true innovation </span>

investing in
true innovation

In 2000, Lennart Perlhagen made the first investment in Novocure, leading to the founding of what has become a global oncology business – and a decades-long partnership and friendship.

Learn More
5-year IPO <br><span>anniversary</span>

5-year IPO

On October 5, we virtually rang the opening bell at Nasdaq in Times Square in New York City in celebration of our 5-year anniversary of becoming a public company. Read more about our milestone of becoming a public company in 2015.

Learn More

the story
of Novocure

In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.

Learn More

we can leverage physics to fight cancer

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die.


explore our clinical pipeline

Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.


we are dedicated to improving the lives of cancer patients

Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.